SpringWorks Hopes Pediatric Plus Adult Data Make Mirdametinib Go-To For NF1-PN

 
• By Alaric DeArment
  
SpringWorks announced data from its Phase IIb trial of mirdametinib in the rare disease NF1. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D